[{"data":1,"prerenderedAt":170},["ShallowReactive",2],{"drug-vinblastine":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":34,"contraindications":65,"warnings":75,"renal":85,"monitoring":86,"interactions":87,"review":88,"examples":91,"atc":99,"iran":101,"usApproval":121,"links":127,"populations":143},"vinblastine",1,{"fa":7,"en":8},"وین‌بلاستین","Vinblastine","antineoplastic-immunomodulating",{"fa":11,"en":12},"آلکالوئید وینکا","Vinca alkaloid",[14],{"name":15,"market":16},"Velban","US",[18,19,20],"velban","ولبان","وینبلاستین",[22],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":29,"refs":30},"inj-1","injection","iv","1 mg\u002FmL, 10 mL vial",{"amount":5,"unit":28,"perVolumeMl":5},"mg",[16],[31],{"source":32,"section":33},"fda-vinblastine","How Supplied",[35],{"id":36,"disease":37,"label":38,"population":41,"type":45,"unit":28,"dose":46,"refs":48,"durationDays":51,"notes":52},"start","hodgkin-lymphoma",{"fa":39,"en":40},"لنفوم هوچکین، سرطان بیضه و سایر بدخیمی‌های پاسخ‌ده (تسکینی) — دوز اول ۳٫۷ mg\u002Fm² وریدی، سپس افزایش هفتگی","Hodgkin lymphoma, testicular cancer and other responsive malignancies (palliative) — first dose 3.7 mg\u002Fm² IV, then weekly increments",{"minAge":42},{"value":43,"unit":44},18,"year","bsa",{"perM2PerDay":47,"dividedDoses":5},3.7,[49],{"source":32,"section":50},"Dosage and Administration",{"min":5,"max":5},[53,59],{"text":54,"refs":57},{"fa":55,"en":56},"فقط زیر نظر پزشک متخصص شیمی‌درمانی و در مرکز مجهز. عدد ماشین‌حساب = mg\u002Fm² برچسب × سطح بدن (Mosteller)؛ پروتکل، فاصله دوره‌ها، تنظیم بر اساس CBC و عملکرد کلیه\u002Fکبد با تیم انکولوژی.","Only under an oncologist in an equipped centre. Calculator = label mg\u002Fm² × BSA (Mosteller); protocol, cycle interval and adjustment for CBC and renal\u002Fhepatic function rest with the oncology team.",[58],{"source":32,"section":50},{"text":60,"refs":63},{"fa":61,"en":62},"افزایش هفتگی بر اساس WBC: ۵٫۵، ۷٫۴، ۹٫۲۵، ۱۱٫۱ mg\u002Fm²؛ حداکثر ۱۸٫۵ mg\u002Fm². فقط وریدی — تزریق داخل نخاعی کشنده است.","Weekly increments by WBC: 5.5, 7.4, 9.25, 11.1 mg\u002Fm²; max 18.5 mg\u002Fm². IV only — intrathecal injection is fatal.",[64],{"source":32,"section":50},[66],{"id":67,"severity":68,"text":69,"refs":72},"ci","block",{"fa":70,"en":71},"گرانولوسیتوپنی قابل‌توجه (مگر ناشی از خود بیماری)؛ عفونت باکتریال کنترل‌نشده.","Significant granulocytopenia (unless due to the disease treated); uncontrolled bacterial infection.",[73],{"source":32,"section":74},"Contraindications",[76],{"text":77,"refs":80},{"fa":78,"en":79},"هشدار جعبه‌ای: فقط وریدی — تزریق از راه دیگر کشنده است. نشت از رگ باعث آسیب شدید بافت می‌شود.","Boxed warning: IV only — fatal if given by other routes. Extravasation causes severe tissue injury.",[81,83],{"source":32,"section":82},"Boxed Warning",{"source":32,"section":84},"Warnings",[],[],[],{"status":89,"reviewer":90,"date":90},"unverified",null,[92],{"regimen":36,"formulation":23,"input":93,"expect":97},{"ageYears":94,"weightKg":95,"heightCm":96},55,80,180,{"perDose":98,"mlPerDose":98},7.4,[100],"L01CA01",{"status":102,"forms":103,"refs":116},"registered",[104,108,112],{"code":105,"en":106,"fa":107},"01283","VINBLASTINE SULFATE 10MG VIAL","ویال وینبلاستین سولفات ۱۰ میلی‌گرم",{"code":109,"en":110,"fa":111},"12261","VINBLASTINE SULFATE 5MG VIAL","ویال وینبلاستین سولفات ۵ میلی‌گرم",{"code":113,"en":114,"fa":115},"52631","VINBLASTINE SULFATE INJECTION, SOLUTION PARENTERAL 1 mg\u002F1mL 10 mL","محلول تزریقی وینبلاستین سولفات ۱ میلی‌گرم \u002F ۱ میلی‌لیتر ۱۰ میلی‌لیتر",[117],{"source":118,"section":119,"url":120},"darooyab-generic","G-1090\u002FVinblastine","https:\u002F\u002Fwww.darooyab.ir\u002FG-1090\u002FVinblastine",{"kind":122,"refs":123,"id":126},"ANDA",[124],{"source":32,"section":125},"SPL approval \u002F marketing category","ANDA089515",[128,131,135,138,141],{"kind":129,"url":130,"label":126},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=089515",{"kind":132,"url":133,"label":134},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=f073b58e-56d6-4c8d-a2ce-b37719402d77","FDA Vinblastine",{"kind":136,"url":137,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa682848.html",{"kind":139,"url":140,"label":100},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=L01CA01",{"kind":142,"url":120,"label":8},"darooyab",{"pregnancy":144,"lactation":153,"pediatric":162},{"level":145,"text":146,"quote":149,"refs":150},"avoid",{"fa":147,"en":148},"برچسب: می‌تواند به جنین آسیب بزند. در بارداری خطرناک است.","Label: can cause fetal harm. Dangerous in pregnancy.","Vinblastine sulfate can cause fetal harm when administered to a pregnant woman.",[151],{"source":32,"section":152},"Pregnancy Category D",{"level":154,"text":155,"quote":158,"refs":159},"caution",{"fa":156,"en":157},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Because many drugs are excreted in human milk and because of the potential for serious adverse reactions from vinblastine sulfate in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the mother.",[160],{"source":32,"section":161},"Nursing Mothers",{"level":154,"text":163,"quote":166,"refs":167},{"fa":164,"en":165},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The dosage schedule for pediatric patients is indicated under DOSAGE AND ADMINISTRATION .",[168],{"source":32,"section":169},"Pediatric Use",1792444429073]